*Storage: Inert atmosphere,Store in freezer, under -20°C.
Ruxolitinib (INCB18424) is a potent and selective JAK1/2 inhibitor with IC50 values of 3.3 nM and 2.8 nM in cell-free assays. It has a 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy.
Synonyms: INCB18424;INCB 018424
4.5
*For Research Use Only !
Change View
Size | Price | USA Stock *0-1 Day | Global Stock *5-7 Days | In Stock |
1mg | łÇò¶ÊÊ | Inquiry | Inquiry | Login |
5mg | łË§¶ÊÊ | Inquiry | Inquiry | Login |
10mg | ł§Ê¶ÊÊ | Inquiry | Inquiry | Login |
50mg | łÍ˶ÊÊ | Inquiry | Inquiry | Login |
100mg | łò˶ÊÊ | Inquiry | Inquiry | Login |
250mg | łÇËò¶ÊÊ | In Stock | In Stock | Login |
1g | ł§ďò¶ÊÊ | In Stock | In Stock | Login |
5g | łÇ§Çó¶ÊÊ | In Stock | In Stock | Login |
Please Login or Create an Account to: See VIP prices and availability
łÇò¶ÊÊ
łË§¶ÊÊ
ł§Ê¶ÊÊ
łÍ˶ÊÊ
łò˶ÊÊ
łÇËò¶ÊÊ
ł§ďò¶ÊÊ
łÇ§Çó¶ÊÊ
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Franco, Lucas ; Rodrigues, Daniel ; Baumart, Gabriela , et al. ChemRxiv,2025.
Abstract: Rho-associated protein kinases (ROCK) play a pivotal role in various cellular processes and have emerged as therapeutic targets for neurodegenerative diseases such as Alzheimer's disease (AD). Inhibition of ROCK affects the production of key AD pathophysiological markers and reduces neuroinflammation. This study aims to accelerate the identification of effective candidates for neurodegeneration by drug repurposing. By conducting chemical space and crystallographic structure analyses, we developed a pharmacophoric map and optimized it to perform a virtual screening campaign. This approach led to the discovery of novel 6 already approved ROCK inhibitors: ruxolitinib (hROCK1IC50 = 0.025 µM; hROCK2IC50 = 0.007 µM), baricitinib (hROCK1IC50 = 0.019 µM; hROCK2IC50 = 0.011 µM), ponatinib (hROCK1IC50 = 0.197 µM; hROCK2IC50 = 0.056 µM), tivozanib (hROCK1IC50 = 12.86 µM; hROCK2IC50 = 0.856 µM), nialamide (hROCK1IC50 = 18.8 µM; hROCK2IC50 = 29.2 µM) and tucatinib (hROCK1IC50 = 51.45 µM; hROCK2IC50 = 18.62 µM). The results of this study highlight ruxolitinib and baricitinib as potent ROCK inhibitors with IC50 values in the low nanomolar range. Tivozanib showed 15-fold selectivity for ROCK2 over ROCK1. Molecular dynamics simulations with ruxolitinib revealed a tight binding with the ATP-binding site of ROCK1 and ROCK2, with stable bidentate hydrogen bonding interactions with the main chain of amino acid residues in the hinge region of ROCK1 and ROCK2. In addition, ruxolitinib showed selectivity for ROCK enzymes across AGC kinase family, highlighting its interesting ROCK/JAK multitarget profile, which can open new avenues in the discovery of novel multitarget-directed ligands for the treatment of neurodegenerative disorders. Biological validation revealed ruxolitinib’s safety profile against different neuronal and glial cell lines. Further, ruxolitinib reduced the immunolabeling for C3, a glial inflammation marker, in LPS-treated astrocytes. This work highlights ruxolitinib as a promising therapeutic option for Alzheimer's disease and other neurodegenerative conditions and pave the way for the new in vitro/in vivo studies for its repurposing.
Show More >
Keywords: drug repositioning ; virtual screening ; neurodegeneration ; pharmacophore modeling ; JAK inhibitors
Purchased from AmBeed: 941678-49-5
CAS No. : | 941678-49-5 |
Formula : | C17H18N6 |
M.W : | 306.37 |
SMILES Code : | N#CC[C@]([H])(C1CCCC1)N2C=C(C=N2)C3=C4C=CN=C4NC=N3 |
Synonyms : |
INCB18424;INCB 018424
|
MDL No. : | MFCD12031592 |
InChI Key : | HFNKQEVNSGCOJV-OAHLLOKOSA-N |
Pubchem ID : | 25126798 |
GHS Pictogram: | ![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Name | JAK1 ↓ ↑ | JAK2 ↓ ↑ | JAK3 ↓ ↑ | Tyk2 ↓ ↑ | Purity | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Peficitinib | ✔ | 98% | |||||||||||||||||
Go6976 | ✔ | 98% | |||||||||||||||||
AZD-1480 |
++++
JAK2, IC50: 0.26 nM | 98+% | |||||||||||||||||
Ruxolitinib |
+++
JAK1, IC50: 3.3 nM |
++++
JAK2, IC50: 2.8 nM | 98% | ||||||||||||||||
Fedratinib |
+++
JAK2 (V617F), IC50: 3 nM JAK2, IC50: 3 nM | 98% | |||||||||||||||||
WP1066 |
+
JAK2, IC50: 2.3 μM | 98% | |||||||||||||||||
Curcumol | ✔ | 98% | |||||||||||||||||
AZ960 |
++++
JAK2, Ki: 0.45 nM JAK2, IC50: <3 nM | 97% | |||||||||||||||||
GLPG0634 analog | ✔ | 99% | |||||||||||||||||
CEP-33779 |
++++
JAK2, IC50: 1.8 nM | 99% | |||||||||||||||||
FLLL32 |
+
JAK2, IC50: <5 μM | 98% | |||||||||||||||||
WHI-P154 |
+
JAK3, IC50: 1.8 μM | 98% | |||||||||||||||||
Decernotinib |
+++
JAK1, IC50: 11 nM JAK1, Ki: 11 nM |
+++
JAK2, Ki: 13 nM |
++++
JAK3, Ki: 2.5 nM |
+++
TYK2, Ki: 13 nM | 99% | ||||||||||||||
ZM39923 HCl |
+
JAK1, pIC50: 4.4 |
+
JAK3, pIC50: 7.1 | 97% | ||||||||||||||||
Cerdulatinib |
+++
JAK1, IC50: 12 nM |
+++
JAK2, IC50: 6 nM |
+++
JAK3, IC50: 8 nM |
++++
TYK2, IC50: 0.5 nM | 98% | ||||||||||||||
TG101209 |
+++
JAK2, IC50: 6 nM |
+
JAK3, IC50: 169 nM | 99% | ||||||||||||||||
AT9283 |
++++
JAK2, IC50: 1.2 nM |
++++
JAK3, IC50: 1.1 nM | 98% | ||||||||||||||||
Momelotinib |
+++
JAK1, IC50: 11 nM |
++
JAK2, IC50: 18 nM |
+
JAK3, IC50: 155 nM | 98+% | |||||||||||||||
XL019 |
+
JAK1, IC50: 134.3 nM |
++++
JAK2, IC50: 2.2 nM |
+
JAK3, IC50: 214.2 nM | 98% | |||||||||||||||
Tofacitinib |
+
JAK1, IC50: 112 nM |
++
JAK2, IC50: 20 nM |
++++
JAK3, IC50: 1 nM | 98% | |||||||||||||||
Filgotinib |
+++
JAK1, IC50: 10 nM |
++
JAK2, IC50: 28 nM |
+
JAK3, IC50: 810 nM |
+
TYK2, IC50: 116 nM | 99% | ||||||||||||||
Pacritinib |
++
JAK2 (V617F), IC50: 19 nM JAK2, IC50: 23 nM |
+
JAK3, IC50: 520 nM |
++
TYK2, IC50: 50 nM | 97% | |||||||||||||||
Gandotinib |
++
JAK1, IC50: 19.8 nM |
++++
JAK2 (V617F), Ki: 0.245 nM JAK2, IC50: 0.288 nM |
++
JAK3, IC50: 48.0 nM |
++
TYK2, IC50: 44 nM | 98% | ||||||||||||||
Tofacitinib citrate |
++
JAK2, IC50: 20 nM |
++++
JAK3, IC50: 1 nM | 99% | ||||||||||||||||
Oclacitinib maleate |
+++
JAK1, IC50: 10nM |
++
JAK2, IC50: 18nM |
+
JAK3, IC50: 99nM |
+
TYK2, IC50: 84nM | 98+% | ||||||||||||||
NVP-BSK805 2HCl |
++
JAK1, IC50: 31.63 nM |
++++
JAK2, IC50: ~0.5 nM |
++
JAK3, IC50: 18.68 nM |
+++
TYK2, IC50: 10.76 nM | 99+% | ||||||||||||||
FM-381 |
++++
JAK3, IC50: 127 pM | 98% | |||||||||||||||||
Ruxolitinib (S enantiomer) |
+++
JAK1, IC50: 3.3 nM |
++++
JAK2, IC50: 2.8 nM |
++
TYK2, IC50: 19 nM | 98% | |||||||||||||||
Baricitinib |
+++
JAK1, IC50: 5.9 nM |
+++
JAK2, IC50: 5.7 nM |
++
TYK2, IC50: 53 nM | 99% | |||||||||||||||
Target |
|
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT03274778 | Prostate Cancer | Not Applicable | Recruiting | May 1, 2019 | Switzerland ... More >> Istituto Oncologico della Svizzera Italiana (IOSI) Recruiting Bellinzona, Switzerland, 6500 Contact: Ricardo Pereira Mestre, Dr. med. +41 (0)91 811 84 46 Ricardo.PereiraMestre@eoc.ch Contact: Barbara Marongiu +41 (0)91 811 91 20 barbara.marongiu@eoc.ch Less << |
NCT02120417 | - | Terminated(The study was termi... More >>nated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.) Less << | - | - | |
NCT01914484 | Chronic Phase Chronic Myeloid ... More >>Leukemia Accelerated Phase Chronic Myeloid Leukemia Blastic Phase Chronic Myeloid Leukemia Philadelphia Positive Acute Lymphoblastic Leukemia Resistant to Tyrosine Kinase Inhibitor Therapy Less << | Phase 1 Phase 2 | Unknown | July 2016 | Canada, Ontario ... More >> Princess Margaret Hospital / University Health Network Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Sima Bogomilsky, RN BScN CON(C) 416-946-4646 sima.bogomilsky@uhn.on.ca Contact: Sonal Malhotra, M.Sc., Ph.D,CCRP 416-946-4501 ext 3449 sonal.malhotra@uhn.ca Principal Investigator: Dennis Kim, MD/PhD Sub-Investigator: Jeffrey H Lipton, MD/PhD Less << |
NCT02119650 | - | Terminated(The study was termi... More >>nated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.) Less << | - | - | |
NCT03257644 | Atopic Dermatitis | Phase 1 | Suspended(Study is currently o... More >>n hold pending amendment update.) Less << | December 2019 | United States, California ... More >> Children's Hospital of Los Angeles Los Angeles, California, United States, 90027 Rady Children's Hospital - San Diego San Diego, California, United States, 92123 United States, Colorado National Jewish Health Denver, Colorado, United States, 80206 United States, Illinois Northwestern University Department of Dermatology Chicago, Illinois, United States, 60611 United States, Michigan David Fivenson, MD, Dermatology, PLC Ann Arbor, Michigan, United States, 48103 United States, North Carolina Wake Research Associates Raleigh, North Carolina, United States, 27612 United States, Pennsylvania Penn State Hershey Medical Center Hershey, Pennsylvania, United States, 17033 United States, Texas Texas Dermatology and Laser Specialist Clinical Research San Antonio, Texas, United States, 78218 Less << |
NCT03654768 | Chronic Phase Chronic Myelogen... More >>ous Leukemia, BCR-ABL1 Positive Less << | Phase 2 | Recruiting | January 1, 2026 | United States, Oregon ... More >> SWOG Recruiting Portland, Oregon, United States, 97239 Contact: Kendra L. Sweet 813-745-6841 kendra.sweet@moffitt.org Principal Investigator: Kendra L. Sweet Less << |
NCT02593760 | Myelofibrosis | Phase 1 | Completed | - | United States, Florida ... More >> Florida Cancer Specialists-Broadway, Fort Myers Fort Myers, Florida, United States, 33908 Florida Cancer Specialist, North Region Saint Petersburg, Florida, United States, 33705 Florida Cancer Specialists West Palm Beach, Florida, United States, 33401 United States, Ohio Oncology Hematology Care Inc Cincinnati, Ohio, United States, 45242 United States, Tennessee Sarah Cannon Research Institute Nashville, Tennessee, United States, 37203 United States, Texas Uni of Texas - Md Anderson Cancer Center; Dept of Leukemia Houston, Texas, United States, 77030 Canada, Alberta Tom Baker Cancer Centre-Calgary; Clinical Research Unit Calgary, Alberta, Canada, T2N 4N2 Canada, Nova Scotia Queen Elizabeth II Health Sciences Centre; Oncology Halifax, Nova Scotia, Canada, B3H 2Y9 Canada, Quebec Centre Hospitalier De L'Universite De Montreal, Hopital Notre-Dame Montreal, Quebec, Canada, H2L 4M1 Germany Uniklinik RWTH Aachen; Med. Klinik IV; Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammz Aachen, Germany, 52074 Campus Virchow-Klinikum Charité Centrum 14; Medizinische Klinik m.S. Hämatologie u. Onkologie Berlin, Germany, 13353 Italy A.O.U. Citta' Della Salute E Della Scienza-P.O. Molinette;S.C. Ematologia Torino, Piemonte, Italy, 10126 Az. Osp. Di Careggi; Divisione Di Ematologia Firenze, Toscana, Italy, 50135 Less << |
NCT01433445 | Idiopathic Myelofibrosis ... More >> Post Essential Thrombocythemia Myelofibrosis Post Polycythemia-Vera Myelofibrosis Less << | Phase 1 | Active, not recruiting | December 31, 2018 | France ... More >> Novartis Investigative Site Paris, France, 75010 Novartis Investigative Site Villejuif Cedex, France, 94805 Germany Novartis Investigative Site Magdeburg, Germany, 39120 Novartis Investigative Site Mainz, Germany, 55131 Ireland Novartis Investigative Site Dublin, Ireland, DUBLIN 8 Novartis Investigative Site Galway, Ireland Italy Novartis Investigative Site Firenze, FI, Italy, 50134 Novartis Investigative Site Reggio Calabria, RC, Italy, 89124 Novartis Investigative Site Varese, VA, Italy, 21100 United Kingdom Novartis Investigative Site London, United Kingdom, SE1 9RT Less << |
NCT02494882 | Acute Lymphoblastic Leukemia | Phase 1 | Active, not recruiting | June 2019 | United States, New York ... More >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Less << |
NCT01712659 | T Cell Leukemia, Adult ... More >> Leukemia, Adult T-Cell T Cell Leukemia, HTLV I Associated Less << | Phase 2 | Recruiting | November 1, 2021 | United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 Less << |
NCT03558607 | Secondary Acute Myelogenous Le... More >>ukemia Evolving From Myeloproliferative Disorder Less << | PHASE1|PHASE2 | UNKNOWN | 2024-08-31 | Seoul National University Bund... More >>ang Hospital, Seongnam, 13620, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of Less << |
NCT00952289 | MPN (Myeloproliferative Neopla... More >>sms) Less << | Phase 3 | Completed | - | - |
NCT02092324 | Atypical Chronic Myeloid Leuke... More >>mia, BCR-ABL1 Negative Chronic Neutrophilic Leukemia Less << | Phase 2 | Recruiting | - | United States, California ... More >> Stanford Cancer Institute Palo Alto Recruiting Palo Alto, California, United States, 94304 Contact: Jason Gotlib 650-736-1253 gotlib@stanford.org Principal Investigator: Jason Gotlib United States, Georgia Emory University Hospital/Winship Cancer Institute Recruiting Atlanta, Georgia, United States, 30322 Contact: Elliott F. Winton 404-778-4755 ewinton@emory.edu Principal Investigator: Elliott F. Winton United States, Missouri Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Stephen Oh 314-362-8846 stoh@dom.wustl.edu Principal Investigator: Stephen Oh United States, Oregon OHSU Knight Cancer Institute Recruiting Portland, Oregon, United States, 97239 Contact: Kim-Hien Dao 503-494-7894 daok@ohsu.edu Principal Investigator: Kim-Hien Dao United States, Texas UT Southwestern/Simmons Cancer Center-Dallas Recruiting Dallas, Texas, United States, 75390 Contact: Robert H. Collins 214-648-4155 robert.collins@utsouthwestern.edu Principal Investigator: Robert H. Collins M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Jorge E. Cortes 713-794-5783 jcortes@mdanderson.org Principal Investigator: Jorge E. Cortes United States, Utah Huntsman Cancer Institute/University of Utah Recruiting Salt Lake City, Utah, United States, 84112 Contact: Michael W. Deininger 801-213-5684 michael.deininger@hci.utah.edu Principal Investigator: Michael W. Deininger Less << |
NCT00952289 | - | Completed | - | - | |
NCT01730755 | Erythrocytosis, Familial, 2 | NO_LONGER_AVAILABLE | - | Washington University School o... More >>f Medicine, Saint Louis, Missouri, 63110, United States Less << | |
NCT02420717 | Leukemia | Phase 2 | Recruiting | July 2023 | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Less << |
NCT02119663 | - | Terminated(The safety committe... More >>e found no safety issues but recommended halting the study based on a lack of efficacy in a similar trial. The sponsor terminated the trial.) Less << | - | - | |
NCT02119650 | NSCLC (Non-small Cell Lung Car... More >>cinoma) Less << | Phase 2 | Terminated(The study was termi... More >>nated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.) Less << | - | - |
NCT03774082 | Graft vs Host Disease | Phase 2 | Not yet recruiting | June 13, 2025 | - |
NCT02117479 | Pancreatic Cancer | Phase 3 | Terminated(The study was termi... More >>nated early based on the results of the planned interim analysis.) Less << | - | - |
NCT02974647 | Lymphoma | PHASE2 | RECRUITING | 2025-11-25 | University of Miami, Miami, Fl... More >>orida, United States|Northwestern Medicine (Data collection and specimen analysis), Chicago, Illinois, 60611, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Commack, Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester, Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Weill Cornell Medical College, New York, New York, United States|Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale, New York, 11553, United States Less << |
NCT02117479 | - | Terminated(The study was termi... More >>nated early based on the results of the planned interim analysis.) Less << | - | - | |
NCT03333187 | Bone Marrow Fibrosis | Phase 2 | Recruiting | March 20, 2023 | Germany ... More >> Universitätsklinkum Aachen Recruiting Aachen, Germany, 52074 Contact: Edgar Jost, PD Dr. ejost@ukaachen.de Principal Investigator: Edgar Jost, PD Dr. Sub-Investigator: Martina Crysandt, Dr. HELIOS Klinikum Berlin-Buch Recruiting Berlin, Germany, 13125 Contact: Herrad Baurmann, Dr. herrad.baurmann@helios-kliniken.de Principal Investigator: Herrad Baurmann, Dr. Sub-Investigator: Stephan Fuhrmann, Dr. Universitätsklinikum Bonn Recruiting Bonn, Germany, 53105 Contact: Dominik Wolf, Prof. Dr. dominik.wolf@ukb.uni-bonn.de Principal Investigator: Dominik Wolf, Prof. Dr. Sub-Investigator: Karin Mayer, Dr. Universitätsklinikum Düsseldorf Recruiting Düsseldorf, Germany, 40225 Contact: Guido Kobbe, Prof. Dr. Kobbe@med.uni-duesseldorf.de Principal Investigator: Guido Kobbe, Prof. Dr. Sub-Investigator: Thomas Schröder, PD Dr. Universitätsklinikum Essen Recruiting Essen, Germany, 45147 Contact: Joachim Göthert, Dr. Joachim.Goethert@uk-essen.de Principal Investigator: Joachim Göthert, Dr. Sub-Investigator: Jürgen Novotny, PD Dr. Klinikum Frankfurt (Oder) GmbH Not yet recruiting Frankfurt (Oder), Germany, 15236 Contact: Michael Kiehl, Prof. Dr. Contact: Olaf Hopfer, Dr. Principal Investigator: Olaf Hopfer, Dr. Sub-Investigator: Georgios Fellas Universitätsklinkum Halle Recruiting Halle (Saale), Germany, 06120 Contact: Haifa Kathrin Al-Ali, PD Dr. haifa.al-ali@uk-halle.de Principal Investigator: Haifa Kathrin Al-Ali, PD Dr. Sub-Investigator: Nadja Jäkel, Dr. University Medical Center Hamburg-Eppendorf Recruiting Hamburg, Germany, 20246 Contact: Nicolaus Kroeger, Prof. Dr. +49-40-7410-55864 n.kroeger@uke.de Contact: Marion Heinzelmann +49-40-7410-54188 mheinzel@uke.de Principal Investigator: Nicolaus Kroeger, Prof. Dr. Sub-Investigator: Christine Wolschke, Dr. Universitätsklinikum Jena Recruiting Jena, Germany, 07747 Contact: Inken Hilgendorf, PD Dr. Inken.Hilgendorf@med.uni-jena.de Principal Investigator: Inken Hilgendorf, PD Dr. Sub-Investigator: Nils Winkelmann, Dr. University Hospital Leipzig Recruiting Leipzig, Germany, 04103 Contact: Dietger Niederwieser, Prof. Dr. Dietger.Niederwieser@medizin.uni-leipzig.de Principal Investigator: Dietger Niederwieser, Prof. Dr. Sub-Investigator: Vladan Vucinic, Dr. Universitätsmedizin der Johannes Gutenberg-Universität Mainz Recruiting Mainz, Germany, 55131 Contact: Eva Wagner, Dr. eva.wagner@unimedizin-mainz.de Principal Investigator: Eva Wagner-Drouet, Dr. Sub-Investigator: Thomas Kindler, PD Dr. Universitätsmedizin Mannheim Recruiting Mannheim, Germany, 68167 Contact: Stefan Klein, PD Dr. Stefan.Klein@medma.uni-heidelberg.de Principal Investigator: Stefan Klein, PD Dr. Sub-Investigator: Andreas Reiter, Prof. Dr. Johannes Wesling Klinikum Minden Recruiting Minden, Germany, 32429 Contact: Martin Griesshammer, Prof. Dr. martin.griesshammer@muehlenkreiskliniken.de Principal Investigator: Martin Griesshammer, Prof. Dr. Sub-Investigator: Hans-Joachim Tischler, Dr. Universitätsklinikum Münster Recruiting Munster, Germany, 48149 Contact: Matthias Stelljes, Prof. Dr. Matthias.Stelljes@ukmuenster.de Principal Investigator: Eva Eßeling, Dr. Sub-Investigator: Matthias Stelljes, Prof. Dr. Klinikum Nürnberg Recruiting Nürnberg, Germany, 90419 Contact: Kerstin Schäfer-Eckart, Dr. Kerstin.Schaefer-Eckart@klinikum-nuernberg.de Principal Investigator: Kerstin Schäfer-Eckart, Dr. Sub-Investigator: Knut Wendelin, Dr, Robert-Bosch-Krankenhaus Stuttgart Recruiting Stuttgart, Germany, 70376 Contact: Martin Kaufmann, Dr. Martin.Kaufmann@rbk.de Principal Investigator: Martin Kaufmann, Dr. Sub-Investigator: Matthias Vöhringer, Dr. Universitätsmedizin Tübingen Recruiting Tübingen, Germany, 72076 Contact: Wolfgang Bethge, Prof. Dr. Wolfgang.Bethge@med.uni-tuebingen.de Principal Investigator: Wolfgang Bethge, Prof. Dr. Sub-Investigator: Christoph Faul, Dr. Universitätsklinkum Ulm Recruiting Ulm, Germany, 89081 Contact: Konstanze Döhner, Prof. Dr. Konstanze.Doehner@uniklinik-ulm.de Principal Investigator: Konstanze Döhner, Prof. Dr. Sub-Investigator: Frank Stegelmann, Dr. Less << |
NCT02119663 | Pancreatic Cancer | Phase 3 | Terminated(The safety committe... More >>e found no safety issues but recommended halting the study based on a lack of efficacy in a similar trial. The sponsor terminated the trial.) Less << | - | - |
NCT03386214 | Myelofibroses | Phase 1 | Recruiting | March 31, 2021 | United States, Missouri ... More >> Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Stephen Oh, M.D., Ph.D. 314-747-7960 stoh@wustl.edu Principal Investigator: Stephen Oh, M.D., Ph.D. Sub-Investigator: Amy Zhou, M.D. Less << |
NCT01317875 | Myelofibrosis | PHASE1 | COMPLETED | 2019-12-31 | Winter Park, Florida, 32789, U... More >>nited States|Baltimore, Maryland, 21229, United States|Houston, Texas, 77030, United States|Vienna, Austria|Nanjing, Jiangsu, China|Chengdu, Sichuan, China|Hangzhou, Zhejiang, China|Beijing, China|Angers, France|Paris, France|Pierre-Benite, France|Leipzig, Germany|Firenze, Italy|Milano, Italy|Terni, Italy|Rotterdam, Netherlands|Belfast, United Kingdom|London, United Kingdom Less << |
NCT02917096 | Primary Myelofibrosis ... More >> Secondary Myelofibrosis Less << | Not Applicable | Recruiting | October 2019 | United States, California ... More >> City of Hope Medical Center Recruiting Duarte, California, United States, 91010 Contact: Haris Ali 626-256-4673 Principal Investigator: Haris Ali Less << |
NCT01375140 | Myeloproliferative Diseases | Phase 2 | Completed | - | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT02087059 | Primary Myelofibrosis (MF) | PHASE3 | COMPLETED | 2025-04-15 | Novartis Investigative Site, N... More >>agoya-city, Aichi, 467-8602, Japan|Novartis Investigative Site, Matsuyama, Ehime, 790-8524, Japan|Novartis Investigative Site, Toon-city, Ehime, 791-0295, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, 812-8582, Japan|Novartis Investigative Site, Kurume-city, Fukuoka, 830-0011, Japan|Novartis Investigative Site, Maebashi-city, Gunma, 371-8511, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, 060-8543, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, 060-8648, Japan|Novartis Investigative Site, Kobe-city, Hyogo, 650-0017, Japan|Novartis Investigative Site, Kobe-city, Hyogo, 650-0047, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, 860-8556, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, 606-8507, Japan|Novartis Investigative Site, Tsu-city, Mie, 514-8507, Japan|Novartis Investigative Site, Sendai-city, Miyagi, 980-8574, Japan|Novartis Investigative Site, Miyazaki-city, Miyazaki, 889-1692, Japan|Novartis Investigative Site, Okayama-city, Okayama, 700-8558, Japan|Novartis Investigative Site, Hirakata-city, Osaka, 573-1191, Japan|Novartis Investigative Site, OsakaSayama, Osaka, 589-8511, Japan|Novartis Investigative Site, Suita-city, Osaka, 565-0871, Japan|Novartis Investigative Site, Shimotsuke-city, Tochigi, 329-0498, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, 113-8431, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, 113-8519, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, 113-8603, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, 113-8677, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, 160-0023, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, 162-8666, Japan|Novartis Investigative Site, Chuo-city, Yamanashi, 409-3898, Japan|Novartis Investigative Site, Akita, 010-8543, Japan|Novartis Investigative Site, Gifu, 501-1194, Japan Less << |
NCT02087059 | Primary Myelofibrosis (MF) | PHASE3 | COMPLETED | 2025-04-15 | Novartis Investigative Site, N... More >>agoya-city, Aichi, 467-8602, Japan|Novartis Investigative Site, Matsuyama, Ehime, 790-8524, Japan|Novartis Investigative Site, Toon-city, Ehime, 791-0295, Japan|Novartis Investigative Site, Fukuoka-city, Fukuoka, 812-8582, Japan|Novartis Investigative Site, Kurume-city, Fukuoka, 830-0011, Japan|Novartis Investigative Site, Maebashi-city, Gunma, 371-8511, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, 060-8543, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, 060-8648, Japan|Novartis Investigative Site, Kobe-city, Hyogo, 650-0017, Japan|Novartis Investigative Site, Kobe-city, Hyogo, 650-0047, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, 860-8556, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, 606-8507, Japan|Novartis Investigative Site, Tsu-city, Mie, 514-8507, Japan|Novartis Investigative Site, Sendai-city, Miyagi, 980-8574, Japan|Novartis Investigative Site, Miyazaki-city, Miyazaki, 889-1692, Japan|Novartis Investigative Site, Okayama-city, Okayama, 700-8558, Japan|Novartis Investigative Site, Hirakata-city, Osaka, 573-1191, Japan|Novartis Investigative Site, OsakaSayama, Osaka, 589-8511, Japan|Novartis Investigative Site, Suita-city, Osaka, 565-0871, Japan|Novartis Investigative Site, Shimotsuke-city, Tochigi, 329-0498, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, 113-8431, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, 113-8519, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, 113-8603, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, 113-8677, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, 160-0023, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, 162-8666, Japan|Novartis Investigative Site, Chuo-city, Yamanashi, 409-3898, Japan|Novartis Investigative Site, Akita, 010-8543, Japan|Novartis Investigative Site, Gifu, 501-1194, Japan Less << |
NCT03373877 | Myelofibrosis ... More >> Primary Myelofibrosis Post-polycythemia Vera Myelofibrosis Post-essential Thrombocythemia Myelofibrosis Less << | Phase 1 | Recruiting | December 2019 | United States, Connecticut ... More >> Yale Cancer Center Recruiting New Haven, Connecticut, United States, 06511 Contact: Kris Awerkamp, BSN RN CCRP 602-358-8319 kawerkamp@td2inc.com Principal Investigator: Nikolai Podoltsev, MD PhD United States, Louisiana Ochsner Clinic Foundation Recruiting New Orleans, Louisiana, United States, 70121 Contact: Kris Awerkamp, BSN, RN 602-358-8319 kawerkamp@td2inc.com Principal Investigator: Laura Finn, MD United States, Michigan University of Michigan Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Kris Awerkamp, BSN, RN 602-358-8319 kawerkamp@td2inc.com Principal Investigator: Moshe Talpaz, MD Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Kris Awerkamp, BSN, RN 602-358-8319 kawerkamp@td2inc.com Principal Investigator: Jay Yang, MD United States, Nebraska University of Nebraska Medical Center Recruiting Omaha, Nebraska, United States, 68198 Contact: Kris Awerkamp, BSN, RN 602-358-8319 kawerkamp@td2inc.com Principal Investigator: Krishna Gundabolu, MD United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Kris Awerkamp, BSN RN CCRP 602-358-8319 kawerkamp@td2inc.com Principal Investigator: Murat Arcasoy, MD United States, Ohio Cleveland Clinic - Taussig Cancer Institute Recruiting Cleveland, Ohio, United States, 44195 Contact: Kris Awerkamp, BSN RN CCRP 602-358-8319 kawerkamp@td2inc.com Principal Investigator: Moshe Talpaz, MD United States, Pennsylvania Abramson Cancer Center - University of Pennsylvania Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Kris Awerkamp, BSN, RN 602-358-8319 kawerkamp@td2inc.com Principal Investigator: Elizabeth Hexner, MD United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Kris Awerkamp, BSN, RN 602-358-8319 kawerkamp@td2inc.com Principal Investigator: Naveen Pemmaraju, MD Mays Cancer Center UT Health San Antonio Recruiting San Antonio, Texas, United States, 78229-3900 Contact: Kris Awerkamp, BSN, RN, CCRP 602-358-8319 kawerkamp@td2inc.com Principal Investigator: Ruben A. Mesa, MD, FACP Less << |
NCT02913261 | Corticosteroid Refractory Acut... More >>e Graft vs Host Disease Less << | Phase 3 | Recruiting | March 8, 2021 | - |
NCT00639002 | Multiple Myeloma | Phase 2 | Completed | - | United States, California ... More >> Highland, California, United States, 92346 United States, Florida Boynton Beach, Florida, United States, 33435 United States, New York New York, New York, United States, 10011 Less << |
NCT02475655 | HIV Infections | PHASE2 | COMPLETED | 2018-04-04 | Alabama CRS, Birmingham, Alaba... More >>ma, 35294, United States|UCLA CARE Center CRS, Los Angeles, California, 90035, United States|UCSD Antiviral Research Center CRS, San Diego, California, 92103, United States|Ucsf Hiv/Aids Crs, San Francisco, California, 94110, United States|Northwestern University CRS, Chicago, Illinois, 60611, United States|Washington University Therapeutics (WT) CRS, Saint Louis, Missouri, 63110-1010, United States|Weill Cornell Chelsea CRS, New York, New York, 10010, United States|Weill Cornell Uptown CRS, New York, New York, 10065, United States|University of Rochester Adult HIV Therapeutic Strategies Network CRS, Rochester, New York, 14642, United States|Cincinnati Clinical Research Site, Cincinnati, Ohio, 45219, United States|Case Clinical Research Site, Cleveland, Ohio, 44106, United States|Penn Therapeutics, CRS, Philadelphia, Pennsylvania, 19104, United States|The Miriam Hospital Clinical Research Site (TMH CRS) CRS, Providence, Rhode Island, 02906, United States|Vanderbilt Therapeutics (VT) CRS, Nashville, Tennessee, 37204, United States Less << |
NCT00509899 | Myelofibrosis|Polycythemia Ver... More >>a|Thrombocytosis Less << | PHASE1|PHASE2 | COMPLETED | 2025-02-17 | Rochester, Minnesota, United S... More >>tates|Houston, Texas, United States Less << |
NCT02119676 | CRC (Colorectal Cancer) | Phase 2 | Terminated(Substudy 1 was term... More >>inated for futility at interim analysis and Substudy 2 was terminated per sponsor decision.) Less << | - | - |
NCT02119676 | - | Terminated(Substudy 1 was term... More >>inated for futility at interim analysis and Substudy 2 was terminated per sponsor decision.) Less << | - | - | |
NCT02038036 | Polycythemia Vera | Phase 3 | Active, not recruiting | April 8, 2020 | - |
NCT01644110 | Primary Myelofibrosis ... More >> Secondary Myelofibrosis PMF SMF Post-PV MF Post-ET MF Less << | Phase 1 Phase 2 | Recruiting | May 2022 | Germany ... More >> University of Ulm Recruiting Ulm, Germany, 89081 Contact: Konstanze Doehner, MD konstanze.doehner@uniklinik-ulm.de Principal Investigator: konstanze Doehner, Md Less << |
NCT00509899 | Myelofibrosis|Polycythemia Ver... More >>a|Thrombocytosis Less << | PHASE1|PHASE2 | COMPLETED | 2025-02-17 | Rochester, Minnesota, United S... More >>tates|Houston, Texas, United States Less << |
NCT02997280 | Graft Vs Host Disease | Phase 2 | Recruiting | June 2019 | Russian Federation ... More >> First Pavlov State Medical University of St. Petersburg Recruiting Saint-Petersburg, Russian Federation, 197089 Contact: Ivan S. Moiseev, PhD +79217961951 moisiv@mail.ru Contact: Boris V. Afanasyev, Prof +78122334551 coordinatorbmt@gmail.com Less << |
NCT00639002 | - | Completed | - | - | |
NCT00726232 | Myeloproliferative Neoplasm (M... More >>PN) Less << | PHASE2 | TERMINATED | 2018-08-20 | Houston, Texas, 77030, United ... More >>States|Bergamo, Italy|Firenze, Italy|Pavia, Italy Less << |
NCT02120417 | Breast Cancer | Phase 2 | Terminated(The study was termi... More >>nated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.) Less << | - | - |
NCT02292446 | Polycythemia Vera | PHASE3 | COMPLETED | 2017-12-29 | Novartis Investigative Site, L... More >>inz, A-4010, Austria|Novartis Investigative Site, Salzburg, 5020, Austria|Novartis Investigative Site, Wels, A 4600, Austria|Novartis Investigative Site, Antwerp, 2060, Belgium|Novartis Investigative Site, Brugge, 8000, Belgium|Novartis Investigative Site, Bruxelles, 1070, Belgium|Novartis Investigative Site, Leuven, 3000, Belgium|Novartis Investigative Site, Liege, 4000, Belgium|Novartis Investigative Site, Yvoir, 5530, Belgium|Novartis Investigative Site, Pleven, 5800, Bulgaria|Novartis Investigative Site, Plovdiv, 4002, Bulgaria|Novartis Investigative Site, Sofia, 1413, Bulgaria|Novartis Investigative Site, Sofia, 1431, Bulgaria|Novartis Investigative Site, Vancouver, British Columbia, V5Z 1M9, Canada|Novartis Investigative Site, Hamilton, Ontario, L8V 5C2, Canada|Novartis Investigative Site, Vina del Mar, Valparaiso, 2540364, Chile|Novartis Investigative Site, Santiago, 8420383, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Bayonne, Bayonne Cedex, 64109, France|Novartis Investigative Site, Le Mans, Cedex 09, 72037, France|Novartis Investigative Site, Angers Cedex 1, 49033, France|Novartis Investigative Site, Avignon cedex 9, 84902, France|Novartis Investigative Site, Bordeaux, 33076, France|Novartis Investigative Site, Chambéry Cedex, 73011, France|Novartis Investigative Site, Marseille, 13273, France|Novartis Investigative Site, Meaux cedex, 77104, France|Novartis Investigative Site, Metz, 57000, France|Novartis Investigative Site, Mulhouse cedex, 68070, France|Novartis Investigative Site, Nice Cedex, 06202, France|Novartis Investigative Site, Paris, 75010, France|Novartis Investigative Site, Perpignan, 66046, France|Novartis Investigative Site, Pringy cedex, 74374, France|Novartis Investigative Site, Toulouse Cedex 9, 31059, France|Novartis Investigative Site, Vandoeuvre Les Nancy, 54511, France|Novartis Investigative Site, Villejuif Cedex, 94805, France|Novartis Investigative Site, Mannheim, Baden-Wuerttemberg, 68305, Germany|Novartis Investigative Site, Aschaffenburg, 63739, Germany|Novartis Investigative Site, Augsburg, 86150, Germany|Novartis Investigative Site, Bad Soden, 65812, Germany|Novartis Investigative Site, Berlin, 13357, Germany|Novartis Investigative Site, Bottrop, 46236, Germany|Novartis Investigative Site, Eisenach, 99817, Germany|Novartis Investigative Site, Erlangen, 91054, Germany|Novartis Investigative Site, Frankfurt, 60389, Germany|Novartis Investigative Site, Frankfurt, 60596, Germany|Novartis Investigative Site, Friedrichshafen, 88045, Germany|Novartis Investigative Site, Hamburg, 22081, Germany|Novartis Investigative Site, Hamm, 59063, Germany|Novartis Investigative Site, Heidelberg, 69115, Germany|Novartis Investigative Site, Heilbronn, 74072, Germany|Novartis Investigative Site, Koblenz, 56068, Germany|Novartis Investigative Site, Mutlangen, 73557, Germany|Novartis Investigative Site, Stuttgart, 70376, Germany|Novartis Investigative Site, Wuerzburg, 97080, Germany|Novartis Investigative Site, Monterrey, Nuevo Leon, 64000, Mexico|Novartis Investigative Site, Fredrikstad, NO-1603, Norway|Novartis Investigative Site, Tromso, 9038, Norway|Novartis Investigative Site, Lisboa, 1099 023, Portugal|Novartis Investigative Site, Lisboa, 1749-035, Portugal|Novartis Investigative Site, Lulea, SE 971 80, Sweden|Novartis Investigative Site, Uddevalla, 451 80, Sweden|Novartis Investigative Site, Khon Kaen, THA, 40002, Thailand|Novartis Investigative Site, Bangkok, 10400, Thailand|Novartis Investigative Site, Bangkok, 10700, Thailand|Novartis Investigative Site, Chiang Mai, 50200, Thailand Less << |
NCT01348490 | MPN (Myeloproliferative Neopla... More >>sms) Less << | PHASE2 | COMPLETED | 2018-12-19 | Birmingham, Alabama, United St... More >>ates|Beverly Hills, California, United States|Burbank, California, United States|La Jolla, California, United States|Los Angeles, California, United States|Pomona, California, United States|San Diego, California, United States|New Haven, Connecticut, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|Orange City, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Chicago, Illinois, United States|Iowa City, Iowa, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Ann Arbor, Michigan, United States|Southfield, Michigan, United States|Saint Louis, Missouri, United States|Hackensack, New Jersey, United States|Morristown, New Jersey, United States|Somerville, New Jersey, United States|New York, New York, United States|Durham, North Carolina, United States|Hickory, North Carolina, United States|Canton, Ohio, United States|Cleveland, Ohio, United States|Portland, Oregon, United States|Danville, Pennsylvania, United States|Hershey, Pennsylvania, United States|Charleston, South Carolina, United States|Nashville, Tennessee, United States|Houston, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Burlington, Vermont, United States Less << |
NCT02598297 | Early Myelofibrosis With High ... More >>Molecular Risk Mutations Less << | Phase 3 | Completed | - | - |
NCT02257138 | Blasts More Than 20 Percent of... More >> Bone Marrow Nucleated Cells Blasts More Than 20 Percent of Peripheral Blood White Cells Myelodysplastic/Myeloproliferative Neoplasm Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Less << | Phase 1 Phase 2 | Recruiting | February 1, 2019 | United States, Texas ... More >> M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Farhad Ravandi-Kashani 713-745-0394 Principal Investigator: Farhad Ravandi-Kashani Less << |
NCT02396628 | Graft vs Host Disease | Phase 2 | Recruiting | March 2023 | Germany ... More >> Charité - Universitätsmedizin Berlin Recruiting Berlin, Germany, 13353 Principal Investigator: Igor Blau, PD Dr. Sub-Investigator: Il-Kang Na, PD Dr. Sub-Investigator: Giang Lam Vuong, Dr. Universitätsklinikum Bonn Recruiting Bonn, Germany, 53105 Principal Investigator: Dominik Wolf, Prof. Sub-Investigator: Karin Mayer, Dr. Universitätsklinikum Dresden Recruiting Dresden, Germany, 01307 Principal Investigator: Friedrich Stölzel, Dr. Sub-Investigator: Rainer Ordemann, Prof. University Medical Center Recruiting Freiburg, Germany, 79106 Contact: Nikolas von Bubnoff, Professor nikolas.bubnoff@uniklinik-freiburg.de Principal Investigator: Nikolas von Bubnoff, Professor Sub-Investigator: Robert Zeiser, Professor Universitätsklinikum Hamburg Eppendorf Recruiting Hamburg, Germany, 20246 Principal Investigator: Francis Ayuk, PD Dr. Sub-Investigator: Dietlinde Janson, Dr. Universitätsklinikum Heidelberg Recruiting Heidelberg, Germany, 69120 Principal Investigator: Peter Dreger, Prof. Sub-Investigator: Thomas Luft, PD Dr. Universitätsklinikum des Saarlandes Recruiting Homburg, Germany, 66421 Contact: Jörg T. Bittenbring, Dr. Principal Investigator: Jörg T. Bittenbring, Dr. Sub-Investigator: Niels Murawski, PD Dr. Universitätsklinikum Köln Recruiting Köln, Germany, 50937 Contact: Udo Holtick, Dr. Principal Investigator: Udo Holtick, Dr. Sub-Investigator: Christof Scheid, Prof. Sub-Investigator: Marco Herling, Dr. Universitätsklinikum Marburg Recruiting Marburg, Germany, 35043 Contact: Andreas Burchert, Prof. Principal Investigator: Andreas Burchert, Prof. Sub-Investigator: Kristina Sohlbach, Dr. Universitätsklinikum München TU rechts der Isar Recruiting München, Germany, 81675 Principal Investigator: Mareike Verbeek, Dr. Sub-Investigator: Sandra Grass, Dr. Universitätsklinikum Würzburg Recruiting Würzburg, Germany, 97080 Principal Investigator: Götz Grigoleit, Dr. Sub-Investigator: Sabrina Kraus, Dr. Less << |
NCT03144687 | MPN (Myeloproliferative Neopla... More >>sms) Less << | Phase 2 | Recruiting | March 2019 | United States, Arizona ... More >> Arizona Oncology Associates Recruiting Tempe, Arizona, United States, 85284 Contact: Study Coordinator 480-256-1664 Principal Investigator: Kasra Karamlou United States, California UC Irvine Medical Center Recruiting Orange, California, United States, 92868 Contact: Study Coordinator 714-456-5408 Principal Investigator: Angela Fleischman, MD United States, Colorado Anschutz Cancer Pavilion - University Of Colorado Recruiting Aurora, Colorado, United States, 80045 Contact: Study Coordinator 720-848-2587 Principal Investigator: Brandon McMahon United States, Connecticut Norwalk Hospital Recruiting Norwalk, Connecticut, United States, 06856 Contact: Study Coordinator 203-852-2996 Principal Investigator: Richard Frank United States, District of Columbia Georgetown University Hospital Not yet recruiting Washington, District of Columbia, United States, 20007 Contact: Study Coordinator 202-687-0116 Principal Investigator: Craig Kessler United States, Indiana Parkview Research Center Recruiting Fort Wayne, Indiana, United States, 46845 Contact: Study Coordinator 260-425-6831 Principal Investigator: Robert Manges United States, Maryland University Of Maryland - Greenebaum Cancer Center Recruiting Baltimore, Maryland, United States, 21201 Contact: Study Coordinator 410-328-6635 Principal Investigator: Duong United States, Michigan University of Michigan Health System Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Study Coordinator 734-936-3879 Principal Investigator: Moshe Talpaz, MD Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Study Coordinator 313-576-9758 Principal Investigator: Jay Yang Providence Cancer Center Recruiting Southfield, Michigan, United States, 48075 Contact: Study Coordinator 248-849-5332 Principal Investigator: Howard Terebelo United States, New Mexico University Of New Mexico Cancer Center Recruiting Albuquerque, New Mexico, United States, 87102 Contact: Study Coordinator 505-925-0379 Principal Investigator: Arana Yi United States, New York Weill Cornell Medical Centers Not yet recruiting New York, New York, United States, 10065 Contact: Study Coordinator 212-746-2389 Principal Investigator: Ellen Ritchie New York Medical College Not yet recruiting Valhalla, New York, United States, 10595 Contact: Study Coordinator 914-493-8375 Principal Investigator: Karen Seiter United States, North Carolina Duke University Medical Center Not yet recruiting Durham, North Carolina, United States, 27710 Contact: Study Coordinator 919-681-4769 Principal Investigator: Murat Arcasoy United States, Ohio Cleveland Clinic Recruiting Cleveland, Ohio, United States, 44195 Contact: Study Coordinator 216-444-9464 Principal Investigator: Aaron Gerds, MD United States, Oregon Willamette Valley Cancer Institute Recruiting Eugene, Oregon, United States, 97401 Contact: Study Coordinator 281-863-4631 Principal Investigator: Jeff Sharman, MD United States, Texas Texas Oncology San Antonio Recruiting San Antonio, Texas, United States, 78240 Contact: Study Coordinator 210-595-5680 Principal Investigator: Roger Lyons Texas Oncology - Tyler Recruiting Tyler, Texas, United States, 75702 Contact: Study Coordinator 903-579-9800 Principal Investigator: Habte Yimer United States, Virginia University of Virginia Recruiting Charlottesville, Virginia, United States, 22908 Contact: Study Coordinator 434-982-3927 Principal Investigator: Michael Keng, MD Less << |
NCT00638378 | Prostate Cancer | PHASE2 | TERMINATED | 2025-01-09 | Highland, California, United S... More >>tates|Montebello, California, United States|Mountain View, California, United States|Galesburg, Illinois, United States|Overland Park, Kansas, United States|Wichita, Kansas, United States|Grand Rapids, Michigan, United States|Jefferson City, Missouri, United States|Great Falls, Montana, 59405, United States|Cherry Hill, New Jersey, United States|Staten Island, New York, United States|Bismarck, North Dakota, United States|Bethlehem, Pennsylvania, United States|Sumter, South Carolina, United States|Lacey, Washington, United States Less << |
NCT02131584 | Chronic Lymphocytic Leukemia ... More >> Fatigue Less << | Phase 2 | Active, not recruiting | September 30, 2022 | United States, Texas ... More >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT01431209 | Recurrent Diffuse Large B-Cell... More >> Lymphoma Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Less << | Phase 2 | Active, not recruiting | December 2019 | United States, Maryland ... More >> National Institutes of Health Clinical Center Bethesda, Maryland, United States, 20892 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Nebraska University of Nebraska Medical Center Omaha, Nebraska, United States, 68198 Less << |
NCT02436135 | Myelofibrosis | Phase 1 | Completed | - | United States, California ... More >> Stanford Hospital and Clinics Stanford, California, United States, 94305 United States, Michigan University of Michigan Health System Ann Arbor, Michigan, United States, 48109 Less << |
NCT02955940 | Pancreatic Cancer ... More >> Colorectal Cancer (CRC) Breast Cancer Lung Cancer Less << | Phase 2 | Enrolling by invitation | November 2019 | United States, Kentucky ... More >> University of Louisville Louisville, Kentucky, United States, 40202 United States, New York New York Oncology Hematology PC Hudson, New York, United States, 12534 United States, Texas U of Texas M.D. Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT02076191 | Myeloproliferative Neoplasms | Phase 1 Phase 2 | Active, not recruiting | December 2018 | United States, Missouri ... More >> Washington University of St. Louis Saint Louis, Missouri, United States, 63110 United States, New York Roswell Park Cancer Institute Buffalo, New York, United States, 14263 Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Columbia University Medical Center New York, New York, United States, 10032 Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, North Carolina Wake Forest University Baptist Medical Center Winston-Salem, North Carolina, United States, 27157 United States, Ohio Cleveland Clinic Taussig Cancer Center Institute Cleveland, Ohio, United States, 44195 United States, Pennsylvania University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less << |
NCT00638378 | Prostate Cancer | PHASE2 | TERMINATED | 2025-01-09 | Highland, California, United S... More >>tates|Montebello, California, United States|Mountain View, California, United States|Galesburg, Illinois, United States|Overland Park, Kansas, United States|Wichita, Kansas, United States|Grand Rapids, Michigan, United States|Jefferson City, Missouri, United States|Great Falls, Montana, 59405, United States|Cherry Hill, New Jersey, United States|Staten Island, New York, United States|Bismarck, North Dakota, United States|Bethlehem, Pennsylvania, United States|Sumter, South Carolina, United States|Lacey, Washington, United States Less << |
NCT03701698 | Acute GVHD | Phase 2 | Not yet recruiting | October 31, 2021 | China, Shanghai ... More >> Shanghai General Hospital Active, not recruiting Shanghai, Shanghai, China, 200080 Less << |
NCT01562873 | Breast Cancer | PHASE2 | TERMINATED | 2025-06-16 | Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less << |
NCT01776723 | Myelomonocytic Leukemia | PHASE1|PHASE2 | COMPLETED | 2022-05-10 | H. Lee Moffitt Cancer Center a... More >>nd Research Institute, Tampa, Florida, 33612, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21287, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Weill Medical College of Cornell, New York, New York, 10021, United States|Cleveland Clinic, Cleveland, Ohio, 44106, United States Less << |
NCT01562873 | Breast Cancer | PHASE2 | TERMINATED | 2025-06-16 | Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less << |
NCT02400463 | Hemophagocytic Syndrome (HPS) | PHASE2 | COMPLETED | 2020-01-07 | University of Michigan Compreh... More >>ensive Cancer Center, Ann Arbor, Michigan, 48109, United States Less << |
NCT02966353 | Primary Myelofibrosis ... More >> Post-Polycythemia Vera-Myelofibrosis Post-Essential Thrombocythemia Myelofibrosis Less << | Phase 2 | Active, not recruiting | February 15, 2019 | Austria ... More >> Novartis Investigative Site Vienna, Austria, A-1090 Belgium Novartis Investigative Site Antwerpen, Belgium, 2060 Novartis Investigative Site Leuven, Belgium, 3000 Bulgaria Novartis Investigative Site Sofia, Bulgaria, 1413 Novartis Investigative Site Sofia, Bulgaria, 1756 Canada, British Columbia Novartis Investigative Site Vancouver, British Columbia, Canada, V5Z 1M9 Germany Novartis Investigative Site Halle/S., Germany, 06120 Greece Novartis Investigative Site Thessaloniki, GR, Greece, 570 10 Novartis Investigative Site Athens, Greece, 11527 Italy Novartis Investigative Site Bologna, BO, Italy, 40138 Novartis Investigative Site Firenze, FI, Italy, 50134 Novartis Investigative Site Palermo, PA, Italy, 90127 Japan Novartis Investigative Site Bunkyo-ku, Tokyo, Japan, 113-8431 Russian Federation Novartis Investigative Site Moscow, Russian Federation, 125167 Novartis Investigative Site Moscow, Russian Federation, 129110 Novartis Investigative Site Petrozavodsk, Russian Federation, 185019 Spain Novartis Investigative Site Barcelona, Catalunya, Spain, 08036 Novartis Investigative Site Alicante, Comunidad Valenciana, Spain, 03010 Novartis Investigative Site Santiago de Compostela, Galicia, Spain, 15706 Turkey Novartis Investigative Site Istanbul, Turkey, 34093 Novartis Investigative Site Kocaeli, Turkey, 41380 Less << |
NCT02091752 | Primary Myelofibrosis | PHASE2 | TERMINATED | 2025-02-15 | Novartis Investigative Site, L... More >>eipzig, 04103, Germany|Novartis Investigative Site, Firenze, FI, 50134, Italy|Novartis Investigative Site, Madrid, 28034, Spain Less << |
NCT02253277 | Chronic Myeloid Leukemia | Phase 1 Phase 2 | Completed | - | Germany ... More >> Novartis Investigative Site Berlin, Germany, 13353 Novartis Investigative Site Frankfurt, Germany, 60590 Novartis Investigative Site Freiburg, Germany, 79106 Novartis Investigative Site Jena, Germany, 07740 Novartis Investigative Site Leipzig, Germany, 04103 Novartis Investigative Site Mannheim, Germany, 68169 Less << |
NCT02091752 | Primary Myelofibrosis | PHASE2 | TERMINATED | 2025-02-15 | Novartis Investigative Site, L... More >>eipzig, 04103, Germany|Novartis Investigative Site, Firenze, FI, 50134, Italy|Novartis Investigative Site, Madrid, 28034, Spain Less << |
NCT01251965 | Leukemia | PHASE1|PHASE2 | TERMINATED | 2025-07-12 | University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less << |
NCT00726232 | Myeloproliferative Neoplasm (M... More >>PN) Less << | PHASE2 | TERMINATED | 2018-08-20 | Houston, Texas, 77030, United ... More >>States|Bergamo, Italy|Firenze, Italy|Pavia, Italy Less << |
NCT01702064 | Chronic Phase Chronic Myeloid ... More >>Leukemia Less << | Phase 1 | Active, not recruiting | March 2019 | United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 Less << |
NCT02876302 | Inflammatory Breast Cancer (IB... More >>C) Less << | Phase 2 | Recruiting | February 2024 | United States, Maryland ... More >> Johns Hopkins University Recruiting Baltimore, Maryland, United States, 21287 Contact: Vered Stearns, MD vstearn1@jhmi.edu Johns Hopkins at Green Spring Station Recruiting Lutherville, Maryland, United States, 21093 Contact: Vered Stearns, MD Vstearn1@jhmi.edu United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Beth Overmoyer, MD, FACP 617-632-4056 bovermoyer@partners.org Principal Investigator: Beth Overmoyer, MD, FACP United States, Michigan University of Michigan Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Catherine Van Poznak, MD cvanpoz@med.umich.edu United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Tufia Haddad, MD Haddad.Tufia@mayo.edu United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Jeremy Force, MD Jeremy.force@duke.edu United States, Pennsylvania University of Pennslyvania Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Amy Clark, MD Clarkamy@mail.upenn.edu United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Naoto Ueno, MD Nueno@mdanderson.org Less << |
NCT01340651 | Myelofibrosis | PHASE2 | COMPLETED | 2025-07-12 | Scottsdale, Arizona, United St... More >>ates|Winter Park, Florida, United States|Houston, Texas, TX, United States Less << |
NCT01340651 | Myelofibrosis | PHASE2 | COMPLETED | 2025-07-12 | Scottsdale, Arizona, United St... More >>ates|Winter Park, Florida, United States|Houston, Texas, TX, United States Less << |
NCT02155465 | Lung Cancer | Phase 1 Phase 2 | Completed | - | United States, New Jersey ... More >> Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States, 11725 Memorial Sloan Kettering West Harrison Harrison, New York, United States, 10604 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan Kettering at Mercy Medical Center Rockville Centre, New York, United States Memoral Sloan Kettering Cancer Center at Phelps Sleepy Hollow, New York, United States, 10591 Less << |
NCT01445769 | Primary Myelofibrosis|Post-Pol... More >>ycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis Less << | PHASE2 | COMPLETED | 2025-04-13 | Highland, California, United S... More >>tates|La Jolla, California, United States|Los Angeles, California, United States|Jacksonville, Florida, United States|Orange City, Florida, United States|Winter Park, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Ann Arbor, Michigan, United States|Southfield, Michigan, United States|Morristown, New Jersey, United States|Armonk, New York, United States|Hickory, North Carolina, United States|Canton, Ohio, United States|Hazleton, Pennsylvania, United States|Hershey, Pennsylvania, United States|Charleston, South Carolina, United States|Sioux Falls, South Dakota, United States|San Antonio, Texas, United States Less << |
NCT01445769 | Primary Myelofibrosis|Post-Pol... More >>ycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis Less << | PHASE2 | COMPLETED | 2025-04-13 | Highland, California, United S... More >>tates|La Jolla, California, United States|Los Angeles, California, United States|Jacksonville, Florida, United States|Orange City, Florida, United States|Winter Park, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Iowa City, Iowa, United States|Baltimore, Maryland, United States|Ann Arbor, Michigan, United States|Southfield, Michigan, United States|Morristown, New Jersey, United States|Armonk, New York, United States|Hickory, North Carolina, United States|Canton, Ohio, United States|Hazleton, Pennsylvania, United States|Hershey, Pennsylvania, United States|Charleston, South Carolina, United States|Sioux Falls, South Dakota, United States|San Antonio, Texas, United States Less << |
NCT03610971 | Chronic Phase Chronic Myeloid ... More >>Leukemia Chronic Myeloid Leukemia, Chronic Phase Less << | Phase 2 | Not yet recruiting | January 2022 | United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Not yet recruiting Tampa, Florida, United States, 33612 Contact: Anthony McLaughlin 813-745-5941 anthony.mclaughlin@moffitt.org Contact: Kendra Sweet, M.D. 813-745-8986 kendra.sweet@moffitt.org Principal Investigator: Kendra Sweet, M.D. Less << |
NCT01693601 | Myelofibrosis | Phase 1 Phase 2 | Active, not recruiting | February 2019 | United States, New York ... More >> Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Less << |
NCT02015208 | Chronic Lymphocytic Leukemia | PHASE1|PHASE2 | COMPLETED | 2025-07-15 | Sunnybrook Odette Cancer Cente... More >>r, Toronto, Ontario, M4N3M5, Canada Less << |
NCT03571321 | Acute Lymphoblastic Leukemia ... More >> ALL, Childhood ALL Less << | Phase 1 | Not yet recruiting | September 5, 2024 | United States, Illinois ... More >> University of Chicago Medical Center Not yet recruiting Chicago, Illinois, United States, 60637 Contact: Howie Weiner 773-702-2084 hweiner@medicine.bsd.uchicago.edu Contact: Peggy Green, RN (773) 702-0267 mgreen@medicine.bsd.uchicago.edu Principal Investigator: Emily Currant, MD Less << |
NCT03069326 | Myelofibrosis | Phase 2 | Recruiting | February 2019 | United States, New Jersey ... More >> Memorial Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Raajit Rampal, MD, PhD 212-639-2194 United States, New York Memorial Sloan Kettering Commack Recruiting Commack, New York, United States, 11725 Contact: Raajit Rampa, MD, PhD 212-639-2194 Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Raajit Rampal, MD, PhD 212-639-2194 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Raajit Rampal, MD, PhD 212-639-2194 Contact: Ellin Berman, MD 212-639-7762 Principal Investigator: Raajit Rampal, MD, PhD Memorial Sloan Kettering Rockville Centre Recruiting Rockville Centre, New York, United States, 11570 Contact: Raajit Rampal, MD, PhD 212-639-2194 United States, Texas Md Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Prithvira Bose, MD 713-792-7747 Principal Investigator: Prithvira Bose, MD Less << |
NCT01950780 | Alopecia Areata | PHASE2 | COMPLETED | 2025-04-16 | Columbia University Medical Ce... More >>nter, Department of Dermatology, New York, New York, 10032, United States Less << |
NCT02613598 | Hodgkin's Lymphoma ... More >> Lymphoma, Non-Hodgkin Less << | Phase 1 | Recruiting | October 2021 | United States, Michigan ... More >> University of Michgan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48187 Contact: Tycel Phillips, M.D. 734-232-2883 tycelp@umich.edu Principal Investigator: Tycel Phillips, M.D. Less << |
NCT02066532 | Metastatic Breast Cancer ... More >> Breast Carcinoma HER-2 Positive Breast Cancer Less << | Phase 1 Phase 2 | Recruiting | December 2018 | United States, New York ... More >> Mount Sinai Medical Center Recruiting New York, New York, United States, 10029 Contact: Amy Tiersten, MD 212-241-2299 amy.tiersten@mssm.edu Principal Investigator: Amy Tiersten, MD Columbia University Medical Center Recruiting New York, New York, United States, 10032 Contact: Kevin Kalinsky, MD, MS 212-305-1945 KK2693@cumc.columbia.edu Contact: Dan Otap, CCRP 212-342-3970 DO2267@cumc.columbia.edu Principal Investigator: Kevin Kalinsky, MD, MS New York Hospital-Weill Cornell Medical Center Recruiting New York, New York, United States, 10065 Contact: Tessa Cigler, MD 212-821-0644 elc2007@med.cornell.edu Principal Investigator: Tessa Cigler, MD Montefiore Medical Center Recruiting New York, New York, United States, 10461 Contact: Della Makower, MD 718-405-8529 dmakower@montefiore.org Principal Investigator: Della Makower, MD Less << |
NCT03674047 | Other Cancer | Phase 2 | Not yet recruiting | March 31, 2023 | United States, Massachusetts ... More >> Dana Farber Cancer Institute Not yet recruiting Boston, Massachusetts, United States, 02214 Contact: Zachariah DeFilipp, MD 617-724-4000 zdefilipp@mgh.harvard.edu Principal Investigator: Zachariah DeFilipp, MD Less << |
NCT03491215 | Acute Graft Versus Host Diseas... More >>e Less << | PHASE1|PHASE2 | COMPLETED | 2023-02-02 | Novartis Investigative Site, G... More >>ent, 9000, Belgium|Novartis Investigative Site, Laeken, 1020, Belgium|Novartis Investigative Site, Montreal, Quebec, H3T 1C5, Canada|Novartis Investigative Site, Copenhagen, DK-2100, Denmark|Novartis Investigative Site, Lille, 59000, France|Novartis Investigative Site, Nantes Cedex 01, 44093, France|Novartis Investigative Site, Paris 15, 75015, France|Novartis Investigative Site, Paris, 75019, France|Novartis Investigative Site, Rennes, 35022, France|Novartis Investigative Site, Vandoeuvre Les Nancy, 54511, France|Novartis Investigative Site, Genova, GE, 16147, Italy|Novartis Investigative Site, Roma, RM, 00165, Italy|Novartis Investigative Site, Nagoya, Aichi, 466 8560, Japan|Novartis Investigative Site, Saitama, 330 8777, Japan|Novartis Investigative Site, Seoul, 03080, Korea, Republic of|Novartis Investigative Site, Barcelona, Catalunya, 08035, Spain|Novartis Investigative Site, Barcelona, 08041, Spain|Novartis Investigative Site, Madrid, 28009, Spain|Novartis Investigative Site, Madrid, 28046, Spain Less << |
NCT03222609 | Myelofibrosis (MF) | Phase 2 | Recruiting | June 11, 2021 | United States, Alabama ... More >> UAB Comprehensive Cancer Cente /ID# 165464 Recruiting Birmingham, Alabama, United States, 35217 United States, California Ucsd /Id# 164084 Recruiting La Jolla, California, United States, 92037 Usc /Id# 164095 Recruiting Los Angeles, California, United States, 90033 United States, Florida Mayo Clinic /ID# 164201 Recruiting Jacksonville, Florida, United States, 32224 Moffitt Cancer Center /ID# 164082 Recruiting Tampa, Florida, United States, 33612 United States, Illinois University of Chicago /ID# 164115 Recruiting Chicago, Illinois, United States, 60637 United States, Indiana Indiana Blood & Marrow Transpl /ID# 165075 Recruiting Indianapolis, Indiana, United States, 46237 United States, Massachusetts Dana-Farber Cancer Institute /ID# 162675 Recruiting Boston, Massachusetts, United States, 02215 United States, Michigan Henry Ford Hospital /ID# 162682 Recruiting Detroit, Michigan, United States, 48202 United States, New York Weill Cornell Medical College /ID# 162679 Recruiting New York, New York, United States, 10021 United States, Texas MD Anderson Cancer Center /ID# 162683 Recruiting Houston, Texas, United States, 77030 UT Health Cancer Center /ID# 164094 Recruiting San Antonio, Texas, United States, 78229 United States, Utah University of Utah /ID# 164116 Recruiting Salt Lake City, Utah, United States, 84112-5500 United Kingdom Guy's and St Thomas' NHS Found /ID# 164110 Recruiting London, London, City Of, United Kingdom, SE1 9RT Christie NHS Foundation Trust /ID# 164111 Recruiting Manchester, United Kingdom, M20 4BX Less << |
NCT02469974 | Myelofibrosis ... More >> MF Less << | Not Applicable | Withdrawn(no enrollments) | - | - |
NCT03613428 | Acute T Cell Leukemia | Phase 1 Phase 2 | Not yet recruiting | March 30, 2021 | - |
NCT02723994 | Leukemia | Phase 2 | Recruiting | May 2024 | - |
NCT03745651 | Atopic Dermatitis | Phase 3 | Recruiting | September 2020 | United States, Florida ... More >> San Marcus Research Clinic Inc Recruiting Miami, Florida, United States, 33015 Well Pharma Medical Research Corporation Not yet recruiting Miami, Florida, United States, 33143 Forward Clinical Trials Inc Not yet recruiting Tampa, Florida, United States, 33624 United States, Georgia Clinical Research Atlanta Not yet recruiting Stockbridge, Georgia, United States, 30281 United States, Kentucky Derm Research LLC Not yet recruiting Louisville, Kentucky, United States, 40217 Dermatology Specialists PSC Not yet recruiting Louisville, Kentucky, United States, 40241 United States, New Hampshire ActivMed Practices & Research Inc Not yet recruiting Portsmouth, New Hampshire, United States, 03801 United States, New Jersey Hassman Research Institute Not yet recruiting Berlin, New Jersey, United States, 08009 United States, Ohio Synexus Clinical Research US, Inc. - Cincinnati Not yet recruiting Cincinnati, Ohio, United States, 45236 United States, Pennsylvania Paddington Testing Company Inc Not yet recruiting Philadelphia, Pennsylvania, United States, 19103 United States, South Carolina Synexus Clinical Research US, Inc. - Anderson Not yet recruiting Anderson, South Carolina, United States, 29621 United States, Texas Clinical Trials of Texas Incorporated Not yet recruiting San Antonio, Texas, United States, 78229 Center for Clinical Studies Not yet recruiting Webster, Texas, United States, 77598 United States, Virginia Clinical Research Partners LLC Not yet recruiting Henrico, Virginia, United States, 23233 United States, Washington Dermatology Specialists of Spokane Not yet recruiting Spokane, Washington, United States, 99204 Less << |
NCT03112603 | Graft-versus-host Disease (GVH... More >>D) Less << | Phase 3 | Recruiting | January 2022 | - |
NCT03153982 | Head and Neck Squamous Cell Ca... More >>rcinoma Less << | PHASE2 | TERMINATED | 2023-10-18 | University of Arizona Cancer C... More >>enter, Tucson, Arizona, 85724, United States|University of California, San Francisco, San Francisco, California, 94143, United States Less << |
NCT02973711 | Leukemia, Chronic Myeloid | Phase 1 Phase 2 | Recruiting | April 2021 | United States, Michigan ... More >> The University of Michigan Comprehensive Cancer Center Recruiting Ann Arbor, Michigan, United States, 48109 Contact: Patrick Burke, M.D. 734-647-8921 pwburke@umich.edu Principal Investigator: Patrick Burke, M.D. United States, North Carolina Wake Forest University Health Sciences Not yet recruiting Winston-Salem, North Carolina, United States, 27157 Contact: Rupali Bhave, M.D. 336-713-0864 rbhave@wakehealth.edu Contact: Megan Brown-Farmer 336-713-6913 mebrown@wakehealth.edu Less << |
NCT02953678 | Graft-versus-host Disease (GVH... More >>D) Less << | Phase 2 | Active, not recruiting | June 2020 | - |
NCT03745638 | Atopic Dermatitis | Phase 3 | Recruiting | September 2020 | - |
NCT03147742 | Graft-versus-host Disease (GVH... More >>D) Less << | APPROVED_FOR_MARKETING | - | Mayo Clinic Arizona, Phoenix, ... More >>Arizona, 85054, United States|Cancer Transplant Institute at HonorHealth, Scottsdale, Arizona, 85258, United States|City of Hope Medical Center, Duarte, California, 91010, United States|Scripps Clinic, La Jolla, California, 92037, United States|Colorado Blood Cancer Institute, Denver, Colorado, 80218, United States|Nicklaus Children's Hospital, Miami, Florida, 33155, United States|Blood & Marrow Transplant Center, Orlando, Florida, 32804, United States|Northwestern Memorial Hospital, Chicago, Illinois, 60611, United States|University of Illinois Chicago, Chicago, Illinois, 60612, United States|Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, 46237, United States|Cancer Center of Kansas, Wichita, Kansas, 67214, United States|Massachusetts General Hospital, Boston, Massachusetts, 02214, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109-5271, United States|Spectrum Health, Grand Rapids, Michigan, 49503, United States|Mayo Clinic Minnesota, Rochester, Minnesota, 55905, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Rutgers Cancer Institute, New Brunswick, New Jersey, 08903, United States|New Mexico Cancer Center, Albuquerque, New Mexico, 87109, United States|Weill Cornell Medical College, New York, New York, 10021, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Ohio State University, Columbus, Ohio, 43210, United States|Oregon Health & Science University, Portland, Oregon, 97239, United States|Gettysburg Cancer Center, Gettysburg, Pennsylvania, 17325, United States|Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania, 15224, United States|Greenville Health System Cancer Institute, Greenville, South Carolina, 29615, United States|Avera Research Institute, Sioux Falls, South Dakota, 57105, United States|Texas Oncology, Dallas, Texas, 75246, United States|Houston Methodist, Houston, Texas, 77030, United States|Methodist Hospital, San Antonio, Texas, 78229, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109-1024, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States Less << | |
NCT03110822 | Multiple Myeloma | Phase 1 | Recruiting | May 2020 | United States, California ... More >> Comprehensive Blood and Cancer Center Recruiting Bakersfield, California, United States, 93309-0633 Contact: Nicole Henry 661-862-8548 nhenry@cbccusa.com Principal Investigator: Ravindranath Patel, MD California Cancer Associates for Research & Excellence (cCARE) Recruiting Encinitas, California, United States, 92024 Contact: Daniela Slavin, PhD 760-452-3909 dslavin@ccare.com Principal Investigator: Alberto Bessudo, MD Robert A. Moss, M.D., F.A.C.P., Inc. Recruiting Fountain Valley, California, United States, 92708 Contact: Helen Tam 714-641-1128 helen.tam@sbcglobal.net Principal Investigator: Robert A Moss, MD Pacific Cancer Care Recruiting Monterey, California, United States, 93940 Contact: Dorothy Tenney 831-375-4105 dtenney@pacificcancercare.com Principal Investigator: Laura Stampleman, MD Sansum Clinic- Ridley-Tree Cancer Center Recruiting Santa Barbara, California, United States, 93105 Contact: Heidi Heitkamp, PhD 805-879-5091 hheitkam@ridleytreecc.org Principal Investigator: Daniel R Greenwald, MD James R. Berenson M.D. Inc. Recruiting West Hollywood, California, United States, 90069 Contact: Regina Swift, R.N 310-623-1227 rswift@berensononcology.com Principal Investigator: James R Berenson, MD United States, Florida Millennium Oncology Research Clinic Recruiting Pembroke Pines, Florida, United States, 33024 Contact: Maria Contreras, MD 954-266-7885 mcontreras@millenniumoncologyfl.com Principal Investigator: Isaac Levy, MD United States, Maryland Regional Cancer Care Associates (RCCA) MD, LLC Recruiting Bethesda, Maryland, United States, 20817 Contact: Natalie Bongiorno, RN 301-571-2016 nbongiorno@regionalcancercare.org Principal Investigator: Ralph Boccia, MD Less << |
NCT02593929 | Head and Neck Squamous Cell Ca... More >>rcinoma Less << | Early Phase 1 | Withdrawn | - | - |
NCT01790295 | Primary Myelofibrosis ... More >> Post Polycythemia Vera Myelofibrosis Post Essential Thrombocythemia Myelofibrosis Less << | Phase 2 | Active, not recruiting | February 2021 | United States, Georgia ... More >> Emory Hospital Atlanta, Georgia, United States, 30322 United States, Illinois Northwestern University, Robert h. Lurie Comprehensive Cancer Center Chicago, Illinois, United States, 60611 United States, Kansas University of Kansas Cancer Center Westwood, Kansas, United States, 66205 United States, New York Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 United States, North Carolina Wake Forest Baptist Medical Center Winston-Salem, North Carolina, United States, 27103 United States, Ohio Ohio State University Columbus, Ohio, United States, 43210 Canada Princess Margaret Cancer Centre, University of Toronto Toronto, Canada, M5G 2M9 United Kingdom University of Oxford Oxford, United Kingdom, OX3 9DS Less << |
NCT02267278 | Myeloproliferative Diseases | Phase 2 | Completed | - | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT03616184 | Graft-versus-host-disease (GVH... More >>D) Less << | PHASE2 | COMPLETED | 2023-06-12 | Moffitt Cancer Center, Tampa, ... More >>Florida, 33612, United States|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Ohio State University, Columbus, Ohio, 43210, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109, United States Less << |
NCT03681561 | Hodgkin Lymphoma | Phase 1 Phase 2 | Recruiting | March 2024 | United States, Minnesota ... More >> University of Minnesota Recruiting Minneapolis, Minnesota, United States, 55455 Contact: Erin Zielinski 612-624-0937 eezielin@umn.edu Principal Investigator: Veronika Bachanova, MD Less << |
NCT01895842 | Leukemia | PHASE1 | COMPLETED | 2019-04-02 | University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less << |
NCT03123588 | MPN (Myeloproliferative Neopla... More >>sms) Less << | Phase 2 | Recruiting | June 2020 | - |
NCT03514069 | Glioma Gliobl... More >>astoma Less << | Phase 1 | Recruiting | December 2020 | United States, Ohio ... More >> Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Recruiting Cleveland, Ohio, United States, 44195 Contact: Manmeet Ahluwalia, MD 866-223-8100 CancerCenterResearch@ccf.org Principal Investigator: Manmeet Ahluwalia, MD Less << |
NCT02493530 | Myelofibrosis ... More >> Polycythemia Vera Less << | Phase 1 | Recruiting | December 2019 | United States, Arizona ... More >> Mayo Clinic - Arizona Recruiting Phoenix, Arizona, United States, 85054 Contact: Clinical Trials Office 855-776-0015 Principal Investigator: Ruben Mesa, MD United States, Colorado University of Colorado Cancer Center Recruiting Aurora, Colorado, United States, 80045 Contact: Clinical Trials Office 720-848-0018 Principal Investigator: Daniel A Pollyea, MD, MS United States, Tennessee Vanderbilt-Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Clinical Trials Office 800-811-8480 Principal Investigator: Michael R Savona, MD United States, Wisconsin Medical College of Wisconsin Recruiting Milwaukee, Wisconsin, United States, 53226 Contact: Clinical Trials Office 414-805-1118 Principal Investigator: Laura C. Michaelis, MD Less << |
NCT03286530 | Acute Myeloid Leukemia|Acute M... More >>yeloid Leukemia in Remission|Allogeneic Stem Cell Transplantation Less << | PHASE2 | RECRUITING | 2025-12-26 | Beth Israel Deaconess Medical ... More >>Center, Boston, Massachusetts, 02115, United States|Massachusetts General Hospital, Boston, Massachusetts, 02115, United States|Washington University, Saint Louis, Missouri, 63130, United States|The Ohio State University, Columbus, Ohio, 43210, United States|Vanderbilt University, Nashville, Tennessee, 37235, United States|Medical College of Wisconsin, Wauwatosa, Wisconsin, 53226, United States Less << |
NCT03041636 | Malignant Neoplasms Stated as ... More >>Primary Lymphoid Haematopoietic Other Diseases of Blood and Blood-Forming Organs Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Less << | Phase 2 | Recruiting | March 2021 | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact zestrov@mdanderson.org Less << |
NCT03427866 | Myelofibrosis | PHASE2 | ACTIVE_NOT_RECRUITING | 2025-05-25 | Massachusetts General Hospital... More >>, Boston, Massachusetts, 02214, United States|Washington University, Saint Louis, Missouri, 63130, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, 43210, United States|Vanderbilt University, Nashville, Tennessee, 37235, United States Less << |
NCT03722407 | Chronic Myelomonocytic Leukemi... More >>a|Leukemia Less << | PHASE2 | ACTIVE_NOT_RECRUITING | 2025-09-01 | H. Lee Moffitt Cancer Center a... More >>nd Research Institute, Tampa, Florida, 33612, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21231, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States|Weill Medical College of Cornell University, New York, New York, 10021, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States Less << |
NCT02784496 | Myelofibrosis | Phase 2 | Active, not recruiting | September 2020 | United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less << |
NCT02928978 | Ductal Carcinoma In Situ ... More >> Atypical Lobular Hyperplasia Atypical Ductal Hyperplasia Lobular Carcinoma In Situ Less << | Phase 2 | Recruiting | January 2020 | United States, Texas ... More >> Baylor College of Medicine Recruiting Houston, Texas, United States, 77030 Contact: Kristen Otte 713-798-8874 clinical-research@breastcenter.tmc.edu Principal Investigator: Julie Nangia, M.D. Sub-Investigator: Mothaffar Rimawi, M.D. Sub-Investigator: Matthew Ellis, M.D. Sub-Investigator: Maryam Nemati Shaefee, M.D. Sub-Investigator: C. Kent Osborne, M.D. Sub-Investigator: Angela Coscio, M.D. Less << |
NCT02912754 | Leukemia, Lymphocytic, Chronic... More >>, B-Cell Less << | Phase 1 Phase 2 | Not yet recruiting | August 2019 | Canada, Ontario ... More >> Sunnybrook Odette Cancer Center Not yet recruiting Toronto, Ontario, Canada, M4N 3M5 Contact: Geetha Geetha Yogendran, BSc 416-480-5000 ext 89565 geetha.yogendran@sunnybrook.ca Contact: Lindsay McCaw, MSc 416-480-6100 ext 4244 lindsay.mccaw@sunnybrook.ca Principal Investigator: david e spaner, MD Sunnybrook Odette Cancer Center Toronto, Ontario, Canada, M4N3M5 Less << |
NCT02809976 | Vitiligo | Phase 2 | Completed | - | United States, Massachusetts ... More >> Tufts Medical Center Boston, Massachusetts, United States, 02111 Less << |
NCT02041429 | Recurrent Breast Cancer ... More >> Metastatic Breast Cancer Less << | Phase 1 Phase 2 | Active, not recruiting | January 2021 | United States, Massachusetts ... More >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 Less << |
NCT04331665 | COVID-19|Pneumonia | TERMINATED | 2021-03-24 | Princess Margaret Cancer Centr... More >>e, Toronto, Ontario, M5G 2M9, Canada Less << | |
NCT05592015 | T-Cell Large Granular Lymphocy... More >>te Leukemia Less << | PHASE2 | RECRUITING | 2025-12-31 | Memorial Sloan Kettering Cance... More >>r Center, New York, New York, 10065, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, 43210, United States Less << |
NCT05600855 | Transplant-Related Disorder | PHASE2 | COMPLETED | 2024-12-01 | Institute of Hematology & Bloo... More >>d Diseases Hospital, Tianjin, Tianjin, 300020, China Less << |
NCT03959371 | Myelofibrosis | UNKNOWN | 2021-12-31 | ASST Papa Giovanni XXIII, Berg... More >>amo, Italy|U.O. Ematologia, ASST Spedali Civili, Brescia, Italy|U.S.D. Trapianti di Midollo Osseo, ASST Spedali Civili, Brescia, Italy|U.O.C. di Ematologia Clinica, ASST Lecco, Lecco, Italy|U.O. Ematologia, ASST Fatebenefratelli-Sacco, Milan, Italy|U.O. Ematologia, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy|U.O. Ematologia, Grande Ospedale Metropolitano Niguarda, Milan, Italy|U.O. Ematologia, Humanicas Cancer Center, Milan, Italy|U.O. Ematologia, Ospedale San Raffaele, Milan, Italy|U.O. Oncoematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy|Clinica Ematologica, Ospedale San Gerardo, Monza, Italy|Ospedale di Circolo, ASST Sette Laghi, Varese, 21100, Italy Less << | |
NCT01965119 | Relapsed or Refractory Hodgkin... More >> Lymphoma|Primary Mediastinal Large B-cell Lymphoma Less << | PHASE2 | COMPLETED | 2018-09-18 | Busan University Hospital, Bus... More >>an, Korea, Republic of|Dong-A University, Busan, Korea, Republic of|Kosin University Gospel Hospital, Busan, Korea, Republic of|Asan Medical Center, Seoul, 138-736, Korea, Republic of|Korean Cancer Center Hospital, Seoul, 139-706, Korea, Republic of|Chung-Ang University Hospital, Seoul, Korea, Republic of|Wonju Severance Christian Hospital, Wonju, 220-701, Korea, Republic of Less << |
NCT01877005 | Hodgkin's Lymphoma | PHASE2 | COMPLETED | 2018-06-12 | UCL Louvain St Luc, Brussels, ... More >>10200, Belgium|Université Catholique de Louvain Mont Godinne, Yvoir, 5530, Belgium|Chu Cote de Nacre, Caen, 14000, France|Hopital Henri Mondor, Creteil, 94010, France|Chu Dijon, Dijon, 21000, France|Chru de Lille, Lille, 59037, France|Centre Leon Berard, Lyon, 69373, France|Centre Hospitalier Lyon Sud, Lyon, 69495, France|CHU de Nantes, Hotel Dieu, Nantes, 44093, France|Centre Henri Becquerel, Rouen, 76038, France Less << |
NCT04348071 | COVID-19 | PHASE2|PHASE3 | WITHDRAWN | 2025-10-21 | - |
NCT05722912 | Graft-versus-host Disease (GVH... More >>D) Less << | APPROVED_FOR_MARKETING | - | - | |
NCT05398809 | Autoimmune Polyendocrinopathy ... More >>Candidiasis Ectodermal Dystrophy (Apeced)|Alopecia Areata Less << | PHASE2 | RECRUITING | 2027-12-01 | National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less << |
NCT05998408 | Severe Aplastic Anemia|Single ... More >>Lineage Cytopenias, T-LGL|Hypoplastic MDS Less << | PHASE1|PHASE2 | RECRUITING | 2032-06-03 | National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less << |
NCT05663827 | Steroid Refractory GVHD | PHASE3 | COMPLETED | 2022-11-30 | Chang Gung Memorial Hospital, ... More >>Taoyuan, 333, Taiwan Less << |
NCT04338958 | Covid-19 | PHASE2 | COMPLETED | 2021-07-15 | SRH Wald-Klinikum Gera GmbH, G... More >>era, 07548, Germany|University Hospital Jena, Jena, 07747, Germany|UKSH, Campus Lübeck, Lübeck, 23538, Germany|Klinikum der Landeshauptstadt Stuttgart gK?R, Stuttgart, 70174, Germany|Universit?tsklinikum Ulm, Ulm, 89081, Germany|Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH, Villingen-Schwenningen, 78052, Germany Less << |
NCT05599256 | Transplant-Related Disorder | PHASE2 | RECRUITING | 2025-12-01 | Institute of Hematology & Bloo... More >>d Diseases Hospital, Tianjin, Tianjin, 300020, China Less << |
NCT06695507 | Chronic Graft Versus Host Dise... More >>ase Less << | PHASE1 | RECRUITING | 2025-06-28 | Cincinnati Children's Hospital... More >> Medical Center, Cincinnati, Ohio, 45229, United States Less << |
NCT06244862 | Hemophagocytic Syndromes | PHASE2 | NOT_YET_RECRUITING | 2026-02-01 | - |
NCT06008808 | Graft Vs Host Disease|Graft-ve... More >>rsus-host-disease|Graft Versus Host Disease Less << | PHASE1 | RECRUITING | 2026-12-11 | Washington University School o... More >>f Medicine, Saint Louis, Missouri, 63110, United States Less << |
NCT05121142 | Acute-graft-versus-host Diseas... More >>e|Chronic Graft-versus-host-disease|Solid Organ Transplant Less << | PHASE1 | COMPLETED | 2023-05-13 | Cincinnati Children's Hospital... More >> Medical Center, Cincinnati, Ohio, 45229, United States Less << |
NCT05566535 | Polycythemia Vera | UNKNOWN | 2024-08-01 | - | |
NCT04908280 | Discoid Lupus Erythematosus | PHASE2 | COMPLETED | 2024-03-04 | UR Medicine Dermatology Colleg... More >>e Town, Rochester, New York, 14642, United States Less << |
NCT05413356 | Bronchiolitis Obliterans Syndr... More >>ome|Hematologic Malignancy Less << | PHASE2 | UNKNOWN | 2025-01-01 | The first Affiliated Hospital ... More >>of Zhejiang University, Hangzhou, Zhejiang, 310000, China Less << |
NCT05762874 | Myelofibrosis | NOT_YET_RECRUITING | 2025-06-25 | - | |
NCT06462469 | Steroid-refractory Acute Graft... More >> Versus Host Disease Less << | PHASE4 | RECRUITING | 2026-11-05 | Novartis Investigative Site, G... More >>uangzhou City, Guangdong, 510000, China|Novartis Investigative Site, Guangzhou, Guangdong, 510515, China|Novartis Investigative Site, Zhengzhou, Henan, 450052, China|Novartis Investigative Site, Wuhan, Hubei, 430030, China|Novartis Investigative Site, Chang Chun, Jilin, 130021, China|Novartis Investigative Site, Chengdu, Sichuan, 610072, China|Novartis Investigative Site, Hangzhou, Zhejiang, 310003, China|Novartis Investigative Site, Beijing, 100028, China|Novartis Investigative Site, Beijing, 100034, China|Novartis Investigative Site, Beijing, 100039, China|Novartis Investigative Site, Dalian, 116000, China|Novartis Investigative Site, Fuzhou, 350001, China|Novartis Investigative Site, Shanghai, 200025, China|Novartis Investigative Site, Tianjin, 300020, China Less << |
NCT04337359 | Severe/Very Severe COVID-19 Il... More >>lness Less << | NO_LONGER_AVAILABLE | - | - | |
NCT01392443 | Primary Myelofibrosis (MF)|Pos... More >>t-Polycythemia Vera (PV) MF|Post-Essential Thrombocythemia (ET) MF Less << | PHASE2 | COMPLETED | 2017-10-31 | Novartis Investigative Site, B... More >>eijing, Beijing, 100730, China|Novartis Investigative Site, Guangzhou, Guangdong, 51000, China|Novartis Investigative Site, Wuhan, Hubei, 430030, China|Novartis Investigative Site, Nanjing, Jiangsu, 210029, China|Novartis Investigative Site, Suzhou, Jiangsu, 215006, China|Novartis Investigative Site, Chengdu, Sichuan, 610041, China|Novartis Investigative Site, Tianjin, Tianjin, 300020, China|Novartis Investigative Site, Hangzhou, Zhejiang, 310003, China|Novartis Investigative Site, Jinan, 250012, China|Novartis Investigative Site, Shanghai, 200025, China|Novartis Investigative Site, Nagoya, Aichi, 466 8560, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, 812-8582, Japan|Novartis Investigative Site, Maebashi city, Gunma, 371 8511, Japan|Novartis Investigative Site, Kanazawa-city, Ishikawa, 920-8641, Japan|Novartis Investigative Site, Tsu-city, Mie, 514-8507, Japan|Novartis Investigative Site, Suita city, Osaka, 565 0871, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, 113 8655, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, 160 8582, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, 160-0023, Japan|Novartis Investigative Site, Seoul, Korea, 06351, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho Gu, 06591, Korea, Republic of|Novartis Investigative Site, Seoul, 03080, Korea, Republic of|Novartis Investigative Site, Seoul, 03722, Korea, Republic of|Novartis Investigative Site, Kaohsiung, 833, Taiwan|Novartis Investigative Site, Taipei, 10048, Taiwan|Novartis Investigative Site, Taoyuan, 333, Taiwan Less << |
NCT04446806 | Safety and Efficacy | PHASE4 | UNKNOWN | 2021-05-31 | First Affiliated Hospital, Soo... More >>chow University, Suzhou, Jiangsu, 215000, China Less << |
NCT00617994 | Psoriasis | PHASE2 | COMPLETED | 2009-05-31 | Fridley, Minnesota, 55432, Uni... More >>ted States|Rochester, New York, 14623, United States|Austin, Texas, 78759, United States|College Station, Texas, 77840, United States Less << |
NCT05269771 | Polycythemia Vera | AVAILABLE | - | - | |
NCT04492618 | Necrobiosis Lipoidica | PHASE2 | COMPLETED | 2022-03-16 | Mayo Clinic in Arizona, Scotts... More >>dale, Arizona, 85259, United States Less << |
NCT02164500 | Recurrent Classical Hodgkin Ly... More >>mphoma Less << | PHASE2 | COMPLETED | 2019-05-17 | 1st Dept. of Medicine, Cologne... More >> University Hospital, Cologne, 50924, Germany Less << |
NCT04644211 | Essential Thrombocythemia|Poly... More >>cythemia Vera Less << | PHASE2 | RECRUITING | 2025-12-24 | Massachusetts General Hospital... More >>, Boston, Massachusetts, 02115, United States|Beth-Israel Deaconess Medical Center, Boston, Massachusetts, 02215, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less << |
NCT02072057 | Cancer Cachexia | PHASE2 | TERMINATED | 2018-11-30 | Division of Hematology/Oncolgy... More >>, University Clinic of Medicine, Kantonsspital Aarau AG, Aarau, AG, 5001, Switzerland|Division of Hematology/Oncology, Kantonsspital Olten, Olten, SO, 4600, Switzerland Less << |
NCT05021276 | Safety and Efficacy | PHASE4 | UNKNOWN | 2022-12-15 | The First Affiliated Hospital ... More >>of Soochow University, Suzhou, Jiangsu, 215006, China Less << |
NCT04745637 | Primary Myelofibrosis (PMF)|Po... More >>st Polycythemia Myelofibrosis (PPV MF)|Thrombocythemia Myelofibrosis (PET-MF)|Severe/very Severe COVID-19 Illness|Polycythemia Vera (PV)|Steroid Refractory Acute Graft Versus Host Disease (SR AGVHD)|Steroid Refractory Chronic Graft Versus Host Disease (SR CGVHD) Less << | AVAILABLE | - | - | |
NCT05762640 | Haemophagocytic Lymphohistiocy... More >>tosis Less << | PHASE2 | NOT_YET_RECRUITING | 2025-11-27 | - |
NCT05909943 | Neuromyelitis Optica Spectrum ... More >>Disorder Relapse Less << | PHASE1|PHASE2 | WITHDRAWN | 2026-08-01 | Tianjin Medical University Gen... More >>eral Hospital, Tianjin, Tianjin, 300052, China Less << |
NCT04908735 | Hematopoietic Stem Cell Transp... More >>lant (HSCT)|Bronchiolitis Obliterans (BO) Less << | PHASE2 | RECRUITING | 2025-11-25 | University of Minnesota, Minne... More >>apolis, Minnesota, 55455, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States Less << |
NCT05410470 | Myelofibrosis | COMPLETED | 2025-12-21 | - | |
NCT04807777 | Advanced Cutaneous Squamous Ce... More >>ll Carcinoma Less << | PHASE2 | TERMINATED | 2023-10-04 | Columbia University Irving Med... More >>ical Center, New York, New York, 10032, United States Less << |
NCT04355793 | COVID-19 | NO_LONGER_AVAILABLE | - | - | |
NCT05293717 | Chronic Hand Dermatitis | PHASE1|PHASE2 | ACTIVE_NOT_RECRUITING | 2024-12-31 | UR Medicine Dermatology Colleg... More >>e Town, Rochester, New York, 14642, United States Less << |
NCT03801434 | BCR-JAK2 Fusion Protein Expres... More >>sion|Blasts 20 Percent or Less of Peripheral Blood White Cells|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|Blasts More Than 5 Percent of Peripheral Blood White Cells|Blasts Under 20 Percent of Bone Marrow Nucleated Cells|Chronic Eosinophilic Leukemia, Not Otherwise Specified|Eosinophilia|Hepatomegaly|Hypereosinophilic Syndrome|JAK2 Gene Mutation|Splenomegaly|TEL-JAK2 Fusion Protein Expression Less << | PHASE2 | RECRUITING | 2025-11-30 | Stanford Cancer Institute Palo... More >> Alto, Palo Alto, California, 94304, United States|OHSU Knight Cancer Institute, Portland, Oregon, 97201, United States|University of Utah, Salt Lake City, Utah, 84112, United States|Fred Hutchinson cancer research center, Seattle, Washington, 98109, United States Less << |
NCT05998395 | Kohlmeier Degos Disease With N... More >>eurologic Involvement Less << | PHASE1|PHASE2 | ACTIVE_NOT_RECRUITING | 2025-03-15 | National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less << |
NCT05447260 | Myelofibrosis | PHASE4 | UNKNOWN | 2023-12-10 | Qilu Hospital of Shandong Univ... More >>ersity, Jinan, Shandong, China Less << |
NCT06075225 | GVHD|Acute Stem Cell Transplan... More >>t Complications Less << | PHASE2 | NOT_YET_RECRUITING | 2026-09-30 | West China Hospital, Sichuan U... More >>niversity, Chendu, Sichuan, 610041, China Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() | 1mg | 5mg | 10mg |
1 mM 5 mM 10 mM | 3.26mL 0.65mL 0.33mL | 16.32mL 3.26mL 1.63mL | 32.64mL 6.53mL 3.26mL |